Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 188

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 188
---
 2023

        Numerator:

        Net loss attributable to common stockholders
         
        $
        (51,321
        )
         
        $
        (64,732
        )

        Denominator:

        Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders, basic and diluted

        29,828,227

        23,600,107

        Net loss per share attributable to common stockholders, basic and diluted
         
        $
        (1.72
        )
         
        $
        (2.74
        )
       
      Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

        December 31,

        2024

        2023

        Options issued and outstanding

        4,890,843

        3,930,306

        Unvested RSUs

        516,511

        —

        Early exercised common stock subject to future vesting

        —

        5,040

        ESPP authorized for future issuance

        563,731

        337,017

        Total

        5,971,085

        4,272,363

F-24

AN2 Therapeutics, Inc.Notes to Financial Statements — Continued 

Note 12. Restructuring ChargesOn August 8, 2024, the Company announced a reduction of approximately 50% of the Company's workforce, which was approved by the Board in connection with the Company’s planned restructuring following discontinuation of the EBO-301 study and to further extend the Company’s operating capital. In connection with the workforce reduction, the Company recognized severance and other charges of $2.2 million for the year ended December 31, 2024, primarily related to severance payments and other employee termination-related expenses. The severance and other charges were recorded to restructuring charges on the statements of operations and comprehensive loss. The workforce reduction was complete by the end of 2024. Cash payments for severance and other charges of $2.2 million were made in the year ended December 31, 2024. 

Note 13. Segment ReportingThe Company